The use of long-acting injectable antipsychotics in Schizophrenia: Evaluating the evidence

Journal of Clinical Psychiatry

Volumn 77, Issue , 2016, Pages 3-24

  Correll, Christoph U ^a   Citrome, Leslie ^a   Haddad, Peter M ^a   Lauriello, John ^a   Olfson, Mark ^a   Calloway, Stephen M ^a   Kane, John M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ARIPIPRAZOLE LAUROXIL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; DELAYED RELEASE FORMULATION;

AKATHISIA; AKINESIA; ANXIETY; ANXIETY DISORDER; BEHAVIOR DISORDER; CLINICAL PRACTICE; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FAMILY ATTITUDE; FEAR; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; INJECTION SITE PAIN; INSOMNIA; LIMB PAIN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METABOLIC DISORDER; METHODOLOGY; MYALGIA; NEEDLE; PARKINSONISM; PATIENT ATTITUDE; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PHYSICIAN ATTITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SELECTION BIAS; SIDE EFFECT; SOCIAL STIGMA; SOCIAL SUPPORT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; INTRAMUSCULAR DRUG ADMINISTRATION; MENTAL HEALTH SERVICE; PSYCHOLOGY; UTILIZATION; UTILIZATION REVIEW;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRAMUSCULAR; MENTAL HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 84993994730     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15032su1     Document Type: Review

References (142)

1. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216-226.
2. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizo phrenia. Dialogues Clin Neurosci. 2014; 16(4): 505-524.
3. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010; 176(2-3): 109-113.
4. Heres S. Long-acting injectable antipsychotics: an underutilized treatment option. J Clin Psychiatry. 2014; 75(11): 1263-1265.
5. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3): 241-247.
6. Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014; 4(5): 198-219.
7. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbateds chizophrenia. J Clin Psychopharmacol. 2010; 30(3): 235-244.
8. Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75(11): 1254-1260.
9. Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015; 76(8): 1085-1090.
10. Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013; 13(7): 767-783.
11. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015; 72(8): 830-839.
12. Kane JM, Eerdekens M, Lindenmayer J P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003; 160(6): 1125-1132.
13. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizo phrenia. J Clin Psychiatry. 2008; 69(5): 790-799.
14. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010; 116(2-3): 107-117.
15. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010; 13(5): 635-647.
16. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010; 35(10): 2072-2082.
17. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617-624.
18. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40(1): 192-213.
19. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013; 66(suppl):S37-S41.
20. Crawford R, Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry. 1974; 124(0): 385-391.
21. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics. 1975; 16(1): 32-36.
22. Rifkin A, Quitkin F, Rabiner CJ, et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics, I: relapse rates after one year. Arch Gen Psychiatry. 1977; 34(1): 43-47.
23. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med. 1978; 8(1): 59-70.
24. Hogarty GE, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979; 36(12): 1283-1294.
25. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry. 1980; 37(1): 16-24.
26. Barnes TR, Milavic G, Curson DA, et al. Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Soc Psychiatry. 1983; 18(4): 193-199.
27. Kaneno S, Ohkuma T, Yamashita I, et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Rinsho Hyoka (clinical evaluation). 1991; 19: 15-45.
28. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005; 66(5): 638-641.
29. Arango C, Bombín I, González-Salvador T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry. 2006; 21(1): 34-40.
30. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010; 167(2): 181-189.
31. Detke HC, Weiden PJ, Llorca P-M, et al. Open-label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. Poster presented at the NCDEU 51st Annual Meeting; June 13-16, 2011; Boca Raton, FL.
32. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005; 15(1): 111-117.
33. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007; 191(2): 131-139.
34. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacok inetic stu dy. J Clin Psychiatry. 2007; 68(8): 1218-1225.
35. Potapov A, Tsukarzi E, Mosolov S. Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine. Int J Neuropsychopharmacol. 2008; 11:158.
36. Kamijima K, Ishigooka J, Komada Y. Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia. Jpn J Clin Psychopharmacol. 2009; 12: 1199-1222.
37. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010; 35(12): 2367-2377.
38. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010; 7(11): 23-31.
39. Malla A, Chue P, Jordan G, et al. An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis. Clin Schizophr Relat Psychoses. 2016; 9(4): 198-208.
40. Rosenheck RA, Krystal JH, Lew R, et al.; CSP555 Research Group. Long-acting risperidone and oral anti psychotics in unstable sc hizophrenia. N Engl J Med. 2011; 364(9): 842-851.
41. Buckley PF, Schooler NR, Goff DC, et al.; PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015; 41(2): 449-459.
42. Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015; 76(10): 1359-1365.
43. Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015; 72(8): 822-829.
44. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015; 169(1-3): 393-399.
45. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015; 76(5): 554-561.
46. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014; 205(2): 135-144.
47. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957-965.
48. Chang HC, Tang CH, Huang ST, et al. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012; 46(6): 751-756.
49. Rosa F, Schreiner A, Thomas P, et al. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012; 32(4): 267-279.
50. Crivera C, DeSouza C, Kozma CM, et al. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry. 2011; 11(1): 168.
51. Ren XS, Crivera C, Sikirica M, et al. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the Veterans Health Administration. J Clin Pharm Ther. 2011; 36(3): 383-389.
52. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011; 3: 9-14.
53. Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig. 2010; 30(11): 777-787.
54. Girardi P, Serafini G, Pompili M, et al. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry. 2010; 43(2): 66-72.
55. Su K P, Chang HC, Tsai SJ, et al. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health. 2009; 12(Suppl. 3): S118-S121.
56. Lam A, Chue P, Ligate L, et al. P.3.c.068 efficacy outcomes of risperidone long acting injection in patients previously on oral atypicals versus conventional depots. Dur Neuropsychopharmacol. 2009; 19: S549-S550.
57. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Health care System. J Med Econ. 2009; 12(4): 317-324.
58. Beauclair L, Lam A, McCormick J, et al. Impact of risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia. Value Health. 2005; 8(6):A202-A203.
59. Bourin M, Jolliet P, Hery P, et al. Is rehospitalization a measure of the efficacy of neuroleptics in the treatment of schizophrenia? Int J Psychiatry Clin Pract. 1998; 2(4): 275-278.
60. Svestka J, Náhunek K, Cesková E, et al. A 1-year experience with the administration of clopenthixol decanoate in schizophrenic psychoses [in Czech]. Cesk Psychiatr. 1984; 80(3): 146-154.
61. Waldmann KD, Neumann J. Clinical experience with depot neuroleptic treatment [in German]. Z Arztl Fortbild (Jena). 1984; 78(20): 853-856.
62. Michel G, Vásquez R, Basso L. Follow-up study of patients treated with depot phenothiazines in Valparaiso, Chile [in Spanish]. Bol Oficina Sanit Panam. 1981; 91(5): 418-427.
63. Tan CT, Ong TC, Chee KT. The use of fluphenazine decanoate (Modecate)depot therapy in outpatient schizophrenics - a retrospective study. Singapore Med J. 1981; 22(4): 214-218.
64. Arató M, Erdós A. Experience with depot neuroleptics [in Hungarian]. Orv Hetil. 1979; 120(17): 1015-1021.
65. Devito RA, Brink L, Sloan C, et al. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. J Clin Psychiatry. 1978; 39(1): 26-34.
66. Polonowita A, James NM. Fluphenazine decanoate maintenance in schizophrenia: a retrospective study. NZ Med J. 1976; 83(563): 316-318.
67. Lindholm H. The consumption of inpatient psychiatric resources prior to and during treatment with a depot neuroleptic, perphenazine enanthate: a mirror study. Nord J Psychiatry. 1975; 29(6): 513-520.
68. Gottfries CG, Green L. Flupenthixol decanoate - in treatment of out-patients. Acta Psychiatr Scand. 1974; 50(s255): 15-24.
69. Morritt C. Long-acting phenothiazines and schizophrenia. Nurs Mirror Midwives J. 1974; 138(4): 57-59.
70. Johnson DA, Freeman H. Long-acting tranquillizers. Practitioner. 1972; 208(245): 395-400.
71. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand. 1971; 47(4): 420-430.
72. Malm U. Fluphenazine depot: the usefulness of neuroleptics in perspective [in Swedish]. Nord Psykiatr Tidsskr. 1971; 25(4): 309-314.
73. Haddad PM, Kishimoto T, Correll CU, et al. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015; 28(3): 216-221.
74. Schreiner A, Aadamsoo K, Altamura AC, et al. A randomized, active-controlled rater-blinded 2-year study of paliperidone palmitate versus investigators' choice of oral antipsychotic monotherapy in patients with schizophrenia (prosipal). Poster LP-01-013. Poster presented at the 29th International College of Neuropsychopharmacology (CINP) World Congress of Neuropsychopharmacology; June 22-26, 2014; Vancouver, British Columbia, Canada.
75. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6): 603-609.
76. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog N europsych opharmacol Biol Psychiatry. 2011; 35(1): 218-226.
77. Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(4): 1002-1008.
78. McEvoy J P, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014; 311(19): 1978-1987.
79. Nielsen J, Jensen SO, Friis RB, et al. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015; 41(3): 627-636.
80. Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015; 168(1-2): 498-504.
81. Fluphenazine decanoate [package insert]. Schaumburg, IL: APP Pharmaceuticals; 2010.
82. Haldol decanoate 50; Haldol decanoate 100 [package insert]. Beerse, Belgium: Janssen Pharmaceutica; 2011.
83. Risperdal Consta [package insert]. Wallingstown, Little Island, County Cork, Ireland: Janssen Pharmaceutical; 2015.
84. Zyprexa Relprevv [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.
85. Invega Sustenna [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2015.
86. Invega Trinza [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2015.
87. Abilify Maintena [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Company; 2015.
88. Aristada [package insert]. Waltham, MA: Alkermes; 2015.
89. Luedecke D, Schöttle D, Karow A, et al. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015; 29(1): 41-46.
90. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951-962.
91. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002; 73(4): 297-311.
92. Velligan DI, Weiden PF, Sajatovic M, et al.; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70(suppl 4): 1-46, quiz 47-48.
93. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry. 2007; 68(suppl 6): 14-23.
94. Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics [Epub ahead of print August 4, 2016]. Schizophr Res.
95. Citrome L. Quantifying clinical relevance. Innov Clin Neurosci. 2014; 11(5-6): 26-30.
96. Citrome L. Relative vs absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand. 2010; 121(2): 94-102.
97. Citrome L, Ketter TA. When does a difference make a difference? interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013; 67(5): 407-411.
98. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013; 27(11): 879-911.
99. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015; 69(9): 978-997.
100. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised longterm trials. Schizophr Res. 2011; 127(1-3): 83-92.
101. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013; 74 (6): 568-575.
102. Baloush-Kleinman V, Levine SZ, Roe D, et al. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res. 2011; 130(1-3): 176-181.
103. Huang XY, Hung BJ, Sun FK, et al. The experiences of carers in Taiwanese culture who have long-term schizophrenia in their families: a phenomenological study. J Psychiatr Ment Health Nurs. 2009; 16(10): 874-883.
104. Klingberg S, Schneider S, Wittorf A, et al. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Res. 2008; 161(2): 225-234.
105. Meier J, Becker T, Patel A, et al. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc. 2010; 19(3): 251-259.
106. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10): 1542-1550.
107. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58(9): 1187-1192.
108. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006; 32(4): 724-742.
109. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67(3): 453-460.
110. Mond J, Morice R, Owen C, et al. Use of antipsychotic medications in Australia between July 19 95 and December 2001. Aust NZ J Psychiatry. 2003; 37(1): 55-61.
111. Barnett PG, Scott JY, Krystal JH, et al.; CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012; 73(5): 696-702.
112. Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015; 18(5): 357-365.
113. Bera R, Offord S, Zubek D, et al. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. J Clin Psychopharmacol. 2014; 34(1): 30-35.
114. Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013; 40(3): 355-366.
115. Bin-Chia D, Le EHM, Chung WS, et al. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorder in Hong Kong: an approach using generalized estimating equations. Psychol Res. 2013; 210: 745-750.
116. Young CL, Taylor DM. Health resource utilization associated with switching to risperid one long-acting injection. Acta Psychiatr Scand. 2006; 114(1): 14-20.
117. Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014; 68(6): 416-427.
118. Hong J, Novick D, Brugnoli R, et al. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia. Hum Psychopharmacol. 2013; 28(5): 438-446.
119. Lachaine J, Lapierre ME, Abdalla N, et al. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Can J Psychiatry. 2015; 60(Suppl 2):S40-S47.
120. Lehman AF, Lieberman JA, Dixon LB, et al.; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 suppl): 1-56.
121. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005; 39 (1-2): 1-30.
122. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004; 30(2): 193-217.
123. Psychosis and schizophrenia in adults: prevention and management. NICE Guidelines CG178. National Institute for Health and Care Excellence (NICE) Web site. https://www.nice.org.uk/guidance/cg178?unlid=3595877802015121882226. Updated 2014.
124. Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007; 22(5): 275-282.
125. Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient p and attitudes are not the same thing. J Psychopharmacol. 2009; 23(7): 789-796.
126. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003; 33(1): 83-89.
127. Patel MX, DE Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005; 12(2): 237-244.
128. Hamann J, Mendel R, Heres S, et al. How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol. 2010; 20(4): 276-279.
129. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medic ation. J Clin Psychiatry. 2006; 67(12): 1948-1953.
130. Patel MX, Haddad PM, Chaudhry IB, et al. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010; 24(10): 1473-1482.
131. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010; 175(1-2): 58-62.
132. Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol. 2014; 4(5): 179-185.
133. Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015; 76(6): 684-690.
134. Rubio G, Martínez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006; 51(8): 531-539.
135. Bardes CL. Def ining "patient-centered medicine". N Engl J Med. 2012; 366(9): 782-783.
136. Tellis-Nayak V. A person-centered workplace: the foundation for person-centered caregiving in long-termcare. J Am Med Dir Assoc. 2007; 8(1): 46-54.
137. Correll CU The role of the extended health care team in successful LAI therapy: education to overcome barriers. J Clin Psychiatry. 2014; 75(9): e25.
138. Lopez LV, Kane JM. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. J Clin Psychiatry. 2015; 76(9): 1249-1250.
139. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004; 65(2): 211-216.
140. Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013; 11(2): 95-106.
141. Detke HC, Correll CU, Liu C, et al. Comparison of outcomes in patients with early phase versus later phase schizophrenia. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) 52nd Annual Meeting; May 29-June 1, 2012; Phoenix, AZ.
142. Hough D, Nasrallah H, Turkoz I, et al. Which schizophrenia patients relapse despite adherence to long-acting antipsychotic therapy? Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) 52nd Annual Meeting; May 29-June 1, 2012; Phoenix, AZ.